TrialBritish journal of haematology2025

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Chezi Ganzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.